title: Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials.
abstract: OBJECTIVE
  We conducted this study to determine whether topiramate at 100 mg/d for the treatment of migraine headache is associated with improved productivity in the workplace.
  
  
  METHODS
  Results were derived from two randomized, double-blind, placebo-controlled trials among migraineurs. The number of hours of absenteeism (A), presenteeism (P), and total lost productivity (TLP) (A + P) were calculated. Results were not adjusted for multiplicity.
  
  
  RESULTS
  A total of 325 (162 in the topiramate group and 163 in the placebo group) of 449 subjects were included. Per person mean monthly A rate was only significantly less for individuals within the topiramate group (1.0 hours per person) versus those in the placebo group (1.5 hours per person) for month 3 (P < 0.05). Per person mean P and TLP rates were significantly lower for individuals in the topiramate group versus those in the placebo group for months 1 through 5 (P < 0.05).
  
  
  CONCLUSIONS
  Findings suggest that topiramate, compared with placebo, is associated with decreased workplace presenteeism and TLP.
authors.affiliation: Department of Health Policy (Drs Lofland, Gagne, and Pizzi), Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. jennifer.lofland@jefferson.edu
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Lofland
authors.forename: Joshua J
authors.initials: JJ
authors.lastname: Gagne
authors.forename: Laura T
authors.initials: LT
authors.lastname: Pizzi
authors.forename: Marcia
authors.initials: M
authors.lastname: Rupnow
authors.forename: Stephen D
authors.initials: SD
authors.lastname: Silberstein
mesh_terms: D000041:Absenteeism; D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D004526:Efficiency; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D000077236:Topiramate; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose